Lv31
250 积分 2022-07-25 加入
Discovery of an Oral, Rule of 5 Compliant, Interleukin 17A Protein–Protein Interaction Modulator for the Potential Treatment of Psoriasis and Other Inflammatory Diseases
21天前
已完结
Discovery of Small Molecule Interleukin 17A Inhibitors with Novel Binding Mode and Stoichiometry: Optimization of DNA-Encoded Chemical Library Hits to In Vivo Active Compounds
21天前
已完结
A Series of Novel, Highly Potent, and Orally Bioavailable Next-Generation Tricyclic Peptide PCSK9 Inhibitors
28天前
已完结
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
28天前
已完结
Cardiac natriuretic peptides
1个月前
已完结
pH Controlled transient cyclization of peptides for increased stability towards oral delivery
1个月前
已完结
Targeting TL1A and DR3: the new frontier of anti-cytokine therapy in IBD
1个月前
已完结
TL1A inhibition for inflammatory bowel disease treatment: From inflammation to fibrosis
1个月前
已完结
TL1A Inhibition in Inflammatory Bowel Disease: A Pipeline Review
1个月前
已完结
Molecular Dynamics Simulations and Experimental Results Provide Insight into Clinical Performance Differences between Sandimmune® and Neoral® Lipid-Based Formulations
1个月前
已完结
皖公网安备34019202002308
